In a phase-II clinical trial in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (BOND-2 study), high intratumoral levels of either EGFR, VEGF-R2 or NRP1 were associated with longer overall survival (OS) of patients receiving targeted combined therapy with monoclonal antibodies cetuximab and bevacizumab (with or without CT), compared with tumors characterized by low EGFR, VEGF-R2 or NRP1 expression [40]. This evidence concerns the gene EGFR and metastatic colorectal cancer.